Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
NCT02988297Phase 2Withdrawn
- Sponsor
- Revalesio Corporation
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
01
Overview
Phase 2, randomised trial in amyotrophic lateral sclerosis (ALS) comparing RNS60 with Placebo (2 arms). Primary endpoint: ALS functional rating scale-revised at 24 weeks. Planned start Oct 2026; status: withdrawn.
02
Drugs
RNS60
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02988297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988297.